Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein - PubMed (original) (raw)
Comparative Study
. 2000 Sep 5;39(35):10619-26.
doi: 10.1021/bi001315u.
Affiliations
- PMID: 10978144
- DOI: 10.1021/bi001315u
Comparative Study
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein
J C Rochet et al. Biochemistry. 2000.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder attributed to the loss of dopaminergic neurons from the substantia nigra. Some surviving neurons are characterized by cytoplasmic Lewy bodies, which contain fibrillar alpha-synuclein. Two mutants of human alpha-synuclein (A53T and A30P) have been linked to early-onset, familial PD. Oligomeric forms of these mutants accumulate more rapidly and/or persist for longer periods of time than oligomeric, human wild-type alpha-synuclein (WT), suggesting a link between oligomerization and cell death. The amino acid sequences of the mouse protein and WT differ at seven positions. Mouse alpha-synuclein, like A53T, contains a threonine residue at position 53. We have assessed the conformational properties and fibrillogenicity of the murine protein. Like WT and the two PD mutants, mouse alpha-synuclein adopts a "natively unfolded" or disordered structure. However, at elevated concentrations, the mouse protein forms amyloid fibrils more rapidly than WT, A53T, or A30P. The fibrillization of mouse alpha-synuclein is slowed by WT and A53T. Inhibition of fibrillization leads to the accumulation of nonfibrillar, potentially toxic oligomers. The results are relevant to the interpretation of the phenotypes of transgenic animal models of PD and suggest a novel approach for testing the cause and effect relationship between fibrillization and neurodegeneration.
Similar articles
- Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA, Harper JD, Lansbury PT Jr. Conway KA, et al. Biochemistry. 2000 Mar 14;39(10):2552-63. doi: 10.1021/bi991447r. Biochemistry. 2000. PMID: 10704204 - Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Conway KA, et al. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):571-6. doi: 10.1073/pnas.97.2.571. Proc Natl Acad Sci U S A. 2000. PMID: 10639120 Free PMC article. - Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT. Rochet JC, et al. J Mol Neurosci. 2004;23(1-2):23-34. doi: 10.1385/jmn:23:1-2:023. J Mol Neurosci. 2004. PMID: 15126689 Review. - Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ, Lansbury PT Jr. Volles MJ, et al. Biochemistry. 2003 Jul 8;42(26):7871-8. doi: 10.1021/bi030086j. Biochemistry. 2003. PMID: 12834338 Review.
Cited by
- Definition of a molecular pathway mediating α-synuclein neurotoxicity.
Burré J, Sharma M, Südhof TC. Burré J, et al. J Neurosci. 2015 Apr 1;35(13):5221-32. doi: 10.1523/JNEUROSCI.4650-14.2015. J Neurosci. 2015. PMID: 25834048 Free PMC article. - Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation.
Marsh JA, Singh VK, Jia Z, Forman-Kay JD. Marsh JA, et al. Protein Sci. 2006 Dec;15(12):2795-804. doi: 10.1110/ps.062465306. Epub 2006 Nov 6. Protein Sci. 2006. PMID: 17088319 Free PMC article. - alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Lo Bianco C, et al. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. doi: 10.1073/pnas.152339799. Epub 2002 Jul 16. Proc Natl Acad Sci U S A. 2002. PMID: 12122208 Free PMC article. - Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M, Rockenstein E, Crews L, Masliah E. Hashimoto M, et al. Neuromolecular Med. 2003;4(1-2):21-36. doi: 10.1385/NMM:4:1-2:21. Neuromolecular Med. 2003. PMID: 14528050 Review. - Cell Biology and Pathophysiology of α-Synuclein.
Burré J, Sharma M, Südhof TC. Burré J, et al. Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):a024091. doi: 10.1101/cshperspect.a024091. Cold Spring Harb Perspect Med. 2018. PMID: 28108534 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous